Aerosol-PFC
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
|
WikiDoc Resources for Aerosol-PFC | |
|
Articles | |
|---|---|
|
Most recent articles on Aerosol-PFC Most cited articles on Aerosol-PFC | |
|
Media | |
|
Powerpoint slides on Aerosol-PFC | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Aerosol-PFC at Clinical Trials.gov Clinical Trials on Aerosol-PFC at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Aerosol-PFC
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Aerosol-PFC Discussion groups on Aerosol-PFC Patient Handouts on Aerosol-PFC Directions to Hospitals Treating Aerosol-PFC Risk calculators and risk factors for Aerosol-PFC
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Aerosol-PFC | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
The applications mission is treatment of pulmonary diseases by aerososolized perfluorocarbon(PFC). This new technology of PFC aerosolization via an introducible jet-nebulizer (Aer-Probe, Trudell) has been demonstrated in several animal studies (Kandler, von der Hardt). Aerosol way of PFC application offers a safe and easy to handle procedure for perfluorocarbon assisted ventilation. Patients with ARDS and neonatal respiratory distress syndrome show sustained improvement in gas exchange and lung mechanics. Ventilator associated lung injury is attenuated by the applied perfluorocarbon, diminishing inflammatory induction of chronic lung disease.
Technology is dedicated to perfluorocabons relatively independent from the molecular structure. It offers the chance to register an appropriate PFC for use as respiratory drug.
Recent invetigations showed after induction of lung injury by repeated saline lung lavage due to surfactant depletion in neonatal piglets, the new ventilatory strategy with aerosolized perfluorocarbon led to a reduction of the initial pulmonary inflammatory reaction and an improvement of gas exchange.
Gene expression of IL-1ß, IL-6, IL-8 and TGF-ß1 in pulmonary tissue was significantly lower in surfactant depleted neonatal piglets with severe respiratory distress syndrome receiving aerosolized perfluorocarbon (Aerosol-PFC) than in the control group ventilated with intermittent mandatory ventilation (von der Hardt, Kandler). In this surfactant piglet model, mRNA expression of inflammation mediated adhesion molecules, such as E-Selectin, P-Selectin and ICAM-1 was effectively diminished by using aerosolized perfluorocarbon (Schoof, von der Hardt). Relative neutrophil infiltration in lung tissue was significantly reduced after treatment with aerosolized perfluorocarbon. Proinflammatory cytokines and intercellular adhesion molecules in porcine lung tissue participating in acute pulmonary inflammatory response were detected and could be modulated by a new protective respiratory support with aerosolized perfluorocarbon.
References
- Kandler, von der Hardt: Am J Respir Crit Care Med. 2001 Jul 1;164(1):31-5 Persistent improvement of gas exchange and lung mechanics by aerosolized perfluorocarbon. (Kandler MA, von der Hardt K, Schoof E, Dotsch J, Rascher W.) Klinik fur Kinder und Jugendliche der Friedrich-Alexander-Universitat, Erlangen-Nurnberg, Germany.
- von der Hardt, Kandler: Pediatr Res. 2002 Feb;51(2):177-82. Aerosolized perfluorocarbon suppresses early pulmonary inflammatory response in a surfactant-depleted piglet model. (von der Hardt K, Schoof E, Kandler MA, Dotsch J, Rascher W.) Klinik fur Kinder und Jugendliche der Friedrich-Alexander-Universitat Erlangen-Nurnberg, D-91054 Erlangen, Germany.
- Schoof, von der Hardt: Eur J Pharmacol. 2002 Dec 20;457(2-3):195-200. Aerosolized perfluorocarbon reduces adhesion molecule gene expression and neutrophil sequestration in acute respiratory distress. (Schoof E, von der Hardt K, Kandler MA, Abendroth F, Papadopoulos T, Rascher W, Dotsch J.) Klinik mit Poliklinik fur Kinder und Jugendliche, Pathologisch-Anatomisches Institut der Friedrich-Alexander-Universitat Erlangen-Nurnberg, Loschgestrasse 15, D-91054 Erlangen, Germany.
External links
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
